Statement by Zimmer Holdings, Inc.
New York Times Article
July 29, 2008
An article in the July 29, 2008 edition of The New York Times on the need for joint registries to effectively track post-market patient outcomes does not provide sufficient context and data about the life-changing and well documented benefits achieved by millions of hip replacement surgery patients. The article also does not provide a fully balanced review of the real-world challenges associated with applying medical device registry data to follow post-market patient outcomes, nor the comprehensive process Zimmer undertook to investigate performance of the Durom® Acetabular Component (Durom Cup) and take rapid action to address surgical training needs in the United States. The Company therefore provides additional information on these important subjects, including its commitment to post-marketing surveillance and vigilance.